European journal of cancer (Oxford, England : 1990)

COVID-19 Vaccination Before Starting Immune Therapy and Survival in Advanced Cancer Patients

Updated

Abstract

Among 281 patients with advanced cancers, 47 (16.7%) received a COVID-19 mRNA vaccine within 100 days before starting immunotherapy.

  • Patients who received the mRNA vaccine showed a significantly improved overall survival of 51.0 months compared to 21.0 months in those who did not.
  • The confidence interval for survival in vaccinated patients was 95%CI 33.9-70.0, while it was 95%CI 17.7-24.3 for non-vaccinated patients.
  • Younger age, female sex, non-head and neck tumors, and recent COVID-19 mRNA vaccination were all independently associated with improved overall survival.
  • COVID-19 mRNA vaccination within 100 days before immunotherapy initiation may enhance long-term survival in patients with various cancer types.
  • Further prospective studies are needed to confirm these findings.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free